Skip to main content
Clinical Trials/NCT04127500
NCT04127500UnknownNot Applicable

The Mechanism of Dexmedetomidine in Improving Delirium After Cardiac Surgery

Nanjing First Hospital, Nanjing Medical University1 site in 1 country200 target enrollmentStarted: August 1, 2019Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Enrollment
200
Locations
1
Primary Endpoint
α7nAChR level

Study Overview

Brief Summary

The investigators aim to evaluate the roles of α7nAchR in the mechanisms of dexmedetomidine in improving delirium after cardiac surgery. The results of this study would lay the foundation for revealing the mechanisms of dexmedetomidine improving delirium after cardiac surgery and provide a new idea to the early treatment of delirium.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Care Provider)

Eligibility Criteria

Ages
60 Years to 100 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • ICU patients underwent cardiac surgery
  • age ≥ 60 years

Exclusion Criteria

  • Preoperative cognitive decline, mental illness,
  • preoperative long-term use of hormone patients,
  • preoperative alcohol dependence,
  • patients with alcohol withdrawal symptoms

Arms & Interventions

DEX group

Experimental

use DEX

Intervention: dexmedetomidine (Drug)

Outcomes

Primary Outcomes

α7nAChR level

Time Frame: 7 days

delirium incidence

Time Frame: 1 month

Secondary Outcomes

  • mechanical ventilation time(7 days)
  • ICU stay time(1 month)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

HONG LIANG

Doctor

Nanjing First Hospital, Nanjing Medical University

Study Sites (1)

Loading locations...

Similar Trials